Company profile

Carsten Brunn
Incorporated in
Fiscal year end

SELB stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


8 Nov 19
18 Jan 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue NaN 13K 10K 903K
Net income -11.99M -16.39M -12.07M -14.65M
Diluted EPS -0.26 -0.37 -0.31 -0.65
Net profit margin NaN% -126108% -120740% -1622%
Operating income -11.79M -16.24M -11.86M -14.5M
Net change in cash 4.03M -1.97M -5.23M -13.09M
Cash on hand 34.23M 30.2M 32.17M 37.4M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 903K 207K 8.08M 6.01M
Net income -65.34M -65.32M -36.21M -25.17M
Diluted EPS -2.92 -3.2 -3.89 -15.13
Net profit margin -7235% -31556% -448% -419%
Operating income -65.02M -63.78M -34.67M -25.3M
Net change in cash -33.22M 11.97M 26.32M 15.75M
Cash on hand 37.4M 70.62M 58.66M 32.34M

Financial data from company earnings reports

13F holders
Current Prev Q Change
Total holders 38 46 -17.4%
Opened positions 4 9 -55.6%
Closed positions 12 20 -40.0%
Increased positions 7 6 +16.7%
Reduced positions 16 19 -15.8%
13F shares
Current Prev Q Change
Total value 39.04M 44.06M -11.4%
Total shares 18.51M 20.8M -11.0%
Total puts 0 4.9K -100.0%
Total calls 30K 32 +93650.0%
Total put/call ratio 0.0 153.1 -100.0%
Largest owners
Shares Value Change
EMG Man 3.63M $6.36M -0.6%
Orbimed Advisors 2.88M $5.04M 0.0%
Polaris Venture Management Co. V, L.L.C. 2.77M $4.85M 0.0%
Wasatch Advisors 2.12M $3.71M -17.0%
Artal 2.1M $3.68M 0.0%
Vanguard 1.51M $2.63M -7.1%
BLK BlackRock 672.12K $1.18M +0.6%
Renaissance Technologies 634.37K $1.11M +34.5%
FMR 538.23K $942K +5.0%
Silver Rock Financial 457.85K $801K 0.0%
Largest transactions
Shares Bought/sold Change
Vivo Capital 0 -546.05K EXIT
FOSUF Fosun International 0 -438.33K EXIT
Wasatch Advisors 2.12M -433.06K -17.0%
NTRS Northern Trust 78.55K -300.55K -79.3%
Renaissance Technologies 634.37K +162.87K +34.5%
Millennium Management 263.03K -144.59K -35.5%
Vanguard 1.51M -114.71K -7.1%
Jane Street 0 -108.97K EXIT
Gsa Capital Partners 0 -83.46K EXIT
N Price T Rowe Associates 104.25K -81.65K -43.9%

Financial report summary

  • We are a development‑stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
  • Our recurring losses from operations and negative cash flows from operations raise substantial doubt regarding our ability to continue as a going concern.
  • Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • The terms of our credit facility place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
  • Our ability to use our net operating loss and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.
  • Our product candidates are based on our ImmTOR technology, which is an unproven approach designed to induce antigen‑specific immune tolerance to biologic drugs. We are very early in our clinical development efforts and may not be successful in our efforts to use our ImmTOR technology to build a pipeline of product candidates and develop marketable drugs.
  • We are applying our ImmTOR technology to antigen-specific immune tolerance for gene therapy involving gene augmentation, replacement or editing. Regulatory authorities in the United States and European Union have limited experience in reviewing and approving gene therapy products, which could affect the time and data required to obtain marketing authorization of any of our product candidates.
  • Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
  • We may conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations or the complexity of regulatory burdens may otherwise adversely impact us.
  • We may not be able to obtain orphan drug designation for our product candidates, and even if we do, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
  • Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • Any breakthrough therapy designation that we may receive from the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.
  • Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or compromise our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • We rely on 3SBio in China as our primary supplier of pegadricase and on other third parties for the manufacture of our product candidates for preclinical and clinical testing, and expect to continue to do so for the foreseeable future. Our reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or that such quantities may not be available at an acceptable cost, or in compliance with regulatory requirements, which could delay, prevent or impair our development or commercialization efforts.
  • Our existing collaborations are important to our business, and future licenses may also be important to us. If we are unable to maintain any of these collaborations, or if these arrangements are not successful, or we are unable to enter into future licenses, our business could be adversely affected.
  • We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials.
  • We have no experience manufacturing our product candidates at commercial scale, and if we decide to establish our own manufacturing facility, we cannot assure you that we can manufacture our product candidates in compliance with regulations at a cost or in quantities necessary to make them commercially viable.
  • Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third‑party payors and others in the medical community necessary for commercial success.
  • We currently have no sales organization. If we are unable to establish effective sales, marketing and distribution capabilities, or enter into agreements with third parties with such capabilities, we may not be successful in commercializing our product candidates if and when they are approved.
  • We face substantial competition, including from biosimilars, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
  • Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or third‑party coverage or reimbursement policies, any of which would have a material adverse effect on our business.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
  • Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being approved, developed or commercialized in a timely manner, which could negatively impact our business.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti‑corruption laws, and anti‑money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can have a material adverse effect on our business.
  • Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
  • If we or our contract manufacturers or other third parties fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
  • If we or our licensors are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.
  • If we are unable to protect the confidentiality of our trade secrets and know‑how, our business and competitive position would be harmed.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property, and our issued patents covering our product candidates could be found invalid or unenforceable or could be interpreted narrowly if challenged in court.
  • The lives of our patents may not be sufficient to effectively protect our products and business.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
  • If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.
  • If we do not obtain additional protection under the Hatch‑Waxman Act and similar foreign legislation extending the terms of our patents for our product candidates, our business may be harmed.
  • Our new corporate strategy and restructuring may not be successful.
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • We have incurred increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.
  • A variety of risks associated with maintaining our subsidiary in Russia or expanding operations internationally could adversely affect our business.
  • Our business and operations would suffer in the event of system failures.
  • Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.
  • The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
  • Our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval.
  • A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • Provisions in our restated certificate of incorporation and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • We could be subject to securities class action litigation.
  • Recently-enacted U.S. Tax reform legislation could adversely affect our business and financial condition.
Content analysis ?
H.S. junior Avg
New words: accredited, affixed, allantoin, allotment, analogize, analogy, antigenic, avoid, breaking, CBER, deferral, investor, IP, JSC, NaN, nontransferable, oxidase, redosing, soluble, steering, symptomatic, tissue, urate, visit, weigh
Removed: appoint, approximated, closed, consisted, Conversely, integrated, IRB, line, modify, morale, organizing, RAC, recovery, resigned, summarize, transitional, trichloroethylene, undertaken